PARD (Poniard Pharmaceuticals) 3-Year RORE % : 0.00% (As of Sep. 2011)


What is Poniard Pharmaceuticals 3-Year RORE %?

Poniard Pharmaceuticals PARD 3-Year RORE % is 0.00 as of Sep. 2011.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Poniard Pharmaceuticals's 3-Year RORE % for the quarter that ended in Sep. 2011 was 0.00%.

The industry rank for Poniard Pharmaceuticals's 3-Year RORE % or its related term are showing as below:

PARD's 3-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -11.54
* Ranked among companies with meaningful 3-Year RORE % only.

Poniard Pharmaceuticals  (OTCPK:PARD) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.

Poniard Pharmaceuticals 3-Year RORE % Related Terms

Poniard Pharmaceuticals 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals 3-Year RORE % Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PARD vs OBMP, NSPX, ATRX: 3-Year RORE % Comparison

For the Biotechnology subindustry, Poniard Pharmaceuticals's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poniard Pharmaceuticals 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Poniard Pharmaceuticals's 3-Year RORE % falls into.


Poniard Pharmaceuticals 3-Year RORE % Calculation

Poniard Pharmaceuticals's 3-Year RORE % for the quarter that ended in Sep. 2011 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -12--54 )/( -102.8-0 )
=42/-102.8
=-40.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2011 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 0.00 mean?
Poniard Pharmaceuticals (PARD) has a 3-Year RORE % of 0.00 as of Sep. 2011. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Poniard Pharmaceuticals and its competitors.
Is Poniard Pharmaceuticals' 3-Year RORE % too high?
Poniard Pharmaceuticals' current 3-Year RORE % is 0.00.
How does Poniard Pharmaceuticals' 3-Year RORE % compare to OBMP and NSPX?
Poniard Pharmaceuticals' 3-Year RORE % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Poniard Pharmaceuticals and its competitors. Poniard Pharmaceuticals's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current 3-Year RORE % is 0.00 as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.